<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Opportunities arise to develop new drug modalities targeting nectin-4, aiming to improve efficacy and safety over Enfortumab Vedotin for various solid tumors. As nectin-4 is highly over-expressed in cancer, overcoming current treatment limitations could offer significant advances in cancer therapeutics.Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6179383/pipeline-nectin-4-targeted-immunotherapies?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=2gr4fd&amp;utm_campaign=2252492+-+Nectin-4-Targeted+Immunotherapies+Pipeline+Competitor+Analysis+Report+2026%3a+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Immunotherapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Pipeline of Nectin-4-Targeted Immunotherapies">"Pipeline of Nectin-4-Targeted Immunotherapies"</a> report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about Nectin-4-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting nectin-4. This report will be prepared on demand within one working day upon order placement. The report lists nectin-4-targeted R&amp;D programs by R&amp;D phase in a tabular format and describes in brief the profile of nectin-4-targeted immunotherapies by drug modality. The cell surface adhesion protein Nectin-4 is a cancer associated antigen over-expressed in many solid tumor types with limited expression in normal tissues. Nectin-4 is closely related to the progression and poor prognosis of malignant tumors. Enfortumab Vedotin (EV) is the first nectin-4-targeting antibody-drug conjugate approved by the US FDA for the treatment of advanced urothelial carcinoma. Thereby, nectin-4 has become a clinically validated and commercially successful cancer target. However, inadequate efficacy has limited progress in the treatment of other solid tumors with EV. Furthermore, side effects caused by EV frequently result in dose reduction and/or treatment termination. Thus, the limitations of EV provides a window of opportunity for novel drug modalities targeting nectin-4 with the promise to improve efficacy and safety. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6179383/pipeline-nectin-4-targeted-immunotherapies?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=2gr4fd&amp;utm_campaign=2252492+-+Nectin-4-Targeted+Immunotherapies+Pipeline+Competitor+Analysis+Report+2026%3a+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Immunotherapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/6kqqu9</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZmFlZWZiMzgtMjQ0Mi00NjUwLThlNGMtZjM3ZGU5YzIzNjE2LTEwMjY3MzctMjAyNi0wNS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Nectin-4-Targeted Immunotherapies Pipeline Competitor Analysis Report 2026: R&D Programs by R&D Phase and Profile of Immunotherapies by Drug Modality

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn